435 related articles for article (PubMed ID: 27232857)
1. AKT in cancer: new molecular insights and advances in drug development.
Mundi PS; Sachdev J; McCourt C; Kalinsky K
Br J Clin Pharmacol; 2016 Oct; 82(4):943-56. PubMed ID: 27232857
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
5. Maximising the potential of AKT inhibitors as anti-cancer treatments.
Brown JS; Banerji U
Pharmacol Ther; 2017 Apr; 172():101-115. PubMed ID: 27919797
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
Cho DC
BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
[TBL] [Abstract][Full Text] [Related]
7. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
Iida M; Harari PM; Wheeler DL; Toulany M
Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
[TBL] [Abstract][Full Text] [Related]
8. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
[TBL] [Abstract][Full Text] [Related]
9. Targeting PI3 kinase/AKT/mTOR signaling in cancer.
Sheppard K; Kinross KM; Solomon B; Pearson RB; Phillips WA
Crit Rev Oncog; 2012; 17(1):69-95. PubMed ID: 22471665
[TBL] [Abstract][Full Text] [Related]
10. AKT as a Therapeutic Target for Cancer.
Song M; Bode AM; Dong Z; Lee MH
Cancer Res; 2019 Mar; 79(6):1019-1031. PubMed ID: 30808672
[TBL] [Abstract][Full Text] [Related]
11. [PI3K inhibitor].
Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
[TBL] [Abstract][Full Text] [Related]
12. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
Popova NV; Jücker M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
14. Akt in cancer: Mediator and more.
Revathidevi S; Munirajan AK
Semin Cancer Biol; 2019 Dec; 59():80-91. PubMed ID: 31173856
[TBL] [Abstract][Full Text] [Related]
15. Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J; Dienstmann R; Serra V; Tabernero J
Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of PI3K-Akt signal pathway to apoptosis of tumor cells].
Huang XL; Cui GH; Zhou KY
Ai Zheng; 2008 Mar; 27(3):331-6. PubMed ID: 18334129
[TBL] [Abstract][Full Text] [Related]
17. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt signalling pathway and cancer.
Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA; Arteaga CL
Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of the Akt pathway in human cancer.
Tokunaga E; Oki E; Egashira A; Sadanaga N; Morita M; Kakeji Y; Maehara Y
Curr Cancer Drug Targets; 2008 Feb; 8(1):27-36. PubMed ID: 18288941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
